Smart Capital Traders
  • Politics
  • Investing
  • Latest News
  • Stocks

Smart Capital Traders

  • Politics
  • Investing
  • Latest News
  • Stocks
Politics

More than 20 GOP attorneys general call on RFK Jr, FDA to reinstate safeguards for abortion drugs

by admin August 13, 2025
August 13, 2025
More than 20 GOP attorneys general call on RFK Jr, FDA to reinstate safeguards for abortion drugs

More than 20 Republican attorneys general are demanding that the Trump administration reinstate safety protocols for the abortion drug mifepristone, saying it poses ‘serious risks to women.’

In a letter obtained by Fox News Digital, 22 attorneys general called on Health and Human Services Secretary Robert F. Kennedy Jr. and Food and Drugs Administration head Martin Makary to bring back safeguards for the pills that were scrapped by the Obama and Biden administrations.

‘Recent comprehensive studies of the real-world effects of the chemical abortion drug mifepristone report that serious adverse events occur 22 times more often than stated on the drug’s label, while the drug is less than half as effective as claimed. These facts directly contradict the drug’s primary marketing message of ‘safe’ and ‘effective,” the letter reads, citing studies published earlier this year by the Ethics and Public Policy Center (EPPA), a Washington, D.C.-based advocacy group.

The EPPA report claims the pill presents harm to women, causing 1 in 10 patients to experience a ‘serious adverse event,’ including hemorrhage, emergency room visits and ectopic pregnancy.

The letter, led by Kansas Attorney General Kris Kobach, comes after Kennedy Jr. asked Makary to review the latest data on mifepristone and its safety.

‘Based on that review, the FDA should consider reinstating safety protocols that it identified as necessary as recently as 2011 in its issuance of a Risk Evaluation and Mitigation Strategy (REMS) for mifepristone, but which were removed by the Obama and Biden administrations,’ the letter reads, adding that the drug should be taken off the market if safeguards cannot be put in place.

‘Alternatively, in light of the serious risks to women who are presently being prescribed this drug without crucial safeguards, and in the event the FDA is unable to reinstate the 2011 safety protocols for mifepristone, the FDA should consider withdrawing mifepristone from the market until it completes its review and can decide on a course of action based on objective safety and efficacy criteria,’ the attorneys general wrote.

Sen. Josh Hawley, R-Mo., also sent a letter to Kennedy Jr. last month urging him to take immediate action to reinstate safety guardrails on mifepristone following the secretary’s commitment to conducting a safety review of the drug.

Makary had previously said that he had no plans to modify policies surrounding mifepristone but that the FDA would act if the data suggested there was a safety issue.

Mifepristone, which is taken with another drug called misoprostol to end an early pregnancy, was first approved by the FDA in 2000 after ‘a thorough and comprehensive review’ found it was safe and effective, according to the agency’s website, which noted that periodic reviews since its approval have not identified new safety concerns.

Last year, the Supreme Court rejected a challenge targeting the drug’s availability. The plaintiffs had sought to restrict access to mifepristone across the country, including in Democrat-led states where abortion remains legal. The court did not rule on whether the FDA acted lawfully when it moved during the Obama and Biden administrations to ease the rules for mifepristone’s use that had been established during the Clinton administration.

Medication abortions made up more than half of all abortions in the U.S. health care system in 2023, according to a study by the Guttmacher Institute.

‘Currently, a woman can obtain a mifepristone abortion by participating in only one telehealth visit with any approved healthcare provider (not necessarily a physician), ordering the drugs through a mail-order pharmacy, and self-administering them,’ the attorneys general wrote. ‘And the prescriber is only required to report an adverse event if he or she becomes aware that the patient has died.’

‘The FDA’s removal of these crucial safety protocols in 2016 (and in 2023) that only five years before the FDA considered necessary begs the question of whether the removal was motivated by considerations other than the safety of patients … The current FDA’s dedication to the health and wellbeing of all Americans is encouraging, as is the much-needed review of mifepristone that Secretary Kennedy has promised,’ the letter concludes.

This post appeared first on FOX NEWS

previous post
Former Navy SEAL Rep. Eli Crane fires off message for ex-President Obama: ‘Probably best to sit this one out’
next post
Ashley Biden files for divorce from husband, Howard Krein, after 13 years of marriage: reports

related articles

‘Squad’ member calls Netanyahu a ‘genocidal maniac,’ sparking...

October 15, 2024

Former Biden doctor asks to delay testimony to...

July 8, 2025

Trump appeared on Joe Rogan’s podcast for nearly...

October 26, 2024

Exiled prince looks to lead Iranian people in...

June 24, 2025

Republicans charge ahead on Trump budget, setting up...

April 4, 2025

SEN BERNIE SANDERS: Two Americas, the people vs....

December 27, 2024

One Republican senator voted against confirming Trump nominee...

April 4, 2025

US-backed Gaza aid group launches bold new system...

July 10, 2025

Ben Carson dispels rumors about joining White House...

November 18, 2024

Elbridge Colby clears hurdle, moves to final vote...

April 8, 2025

    Stay updated with the latest news, exclusive offers, and special promotions. Sign up now and be the first to know! As a member, you'll receive curated content, insider tips, and invitations to exclusive events. Don't miss out on being part of something special.


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Most Popular

    • 1

      Retraction of Forecast Financial Information Plus Announcement on New Metallurgical Testwork Results

      October 15, 2024
    • 2

      Bold Ventures Announces Final Closing of Non-Brokered Private Placement and Insider Subscriptions

      October 19, 2024
    • 3

      As North Korea, Iran and China support Russia’s war, is a ‘new axis’ emerging?

      October 25, 2024
    • 4

      Lode Gold Launches Exploration Program at One of the Largest Land Packages in New Brunswick

      October 19, 2024
    • 5

      Emyria and UWA in Partnership to Commercialise Novel Serotonin-Releasing Agents for Mental Health and Neurology

      October 31, 2024

    Categories

    • Investing (2,273)
    • Latest News (2,300)
    • Politics (2,757)
    • Stocks (898)
    • About us
    • Contact us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: smartcapitaltraders.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.


    Copyright © 2025 smartcapitaltraders.com | All Rights Reserved